Tilray CEO on Possible US Cannabis Reclassification
Speakers
Irwin Simon
— Chairman and CEO, Tilray
Summary
Tilray CEO Irwin Simon discusses the potential US reclassification of cannabis from Schedule I to Schedule III. He explains that Tilray currently cannot sell cannabis in the US but sees a tremendous opportunity to enter the market quickly using its global infrastructure and research. Simon notes the stock's positive reaction and highlights lingering banking law challenges.
- Tilray CEO Irwin Simon discusses potential US cannabis reclassification from Schedule I to Schedule III.
- Tilray currently cannot sell cannabis in the US, but has infrastructure and research ready.
- Simon sees a tremendous opportunity for Tilray to enter the US medical cannabis market.
- He mentions Tilray could be operational in the US within six months of approval.
- The stock rose about 10% on the day of the interview.
- Simon also highlights the difficulty with banking laws for cannabis companies.
- He emphasizes the medical benefits of cannabis, especially for cancer and epilepsy.
- Tilray has international cannabis sales in over 21 countries.
Trade Ideas
Reclassification huge opportunity for Tilray
The reclassification of cannabis from Schedule I to Schedule III in the US would allow Tilray to enter the US market for the first time. Tilray already has global infrastructure, grow capacity, brands, and medical research that can be transplanted quickly, creating a tremendous growth opportunity. Simon states they could be operational within six months of approval.
Up Next
This Bloomberg Markets video, published April 23, 2026, features Irwin Simon discussing TLRY. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: Irwin Simon · Tickers: TLRY